NEUP Stock Analysis: Buy, Sell, or Hold?
NEUP - Neuphoria Therapeutics Inc. Common Stock
$4.70
-0.19 (-3.89%)
▼
5d:
-12.96%
30d:
-11.15%
90d:
+1.29%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 19, 2026
0d
Get Alerted When NEUP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NEUP is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NEUP is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NEUP is currently trading at $4.70, which is considered oversold relative to its 30-day fair value range of $4.91 to $5.38.
Technical Outlook: Technically, NEUP is in a strong uptrend. Immediate support is located at $4.41, while resistance sits at $5.53. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.00 (+48.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEUP is in a strong uptrend. Immediate support is located at $4.41, while resistance sits at $5.53. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.00 (+48.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.91 -
$5.38
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 48.9% below Wall St target ($7.00)
- WARNING: Recommendation downgraded due to -13.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.91 -
$5.38
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.41
Resistance Level
$5.53
Current Trend
Strong Uptrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.93
Wall Street Target
$7.00
(+48.9%)
Share & Embed Analysis
Last updated: June 03, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEUP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
